Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REP 2139-Ca and Pegasys in HBV/HDV Co-infection
NCT02233075Phase 2Completed
- Sponsor
- Replicor Inc.
- Start
- Sep 2014
- Primary completion
- Nov 2016
- Modality
- Antisense DNA, Polymer-based Nanoparticles, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of REP 2139-Mg in hepatitis B (HBV), hepatitis D (HDV), sponsored by Replicor Inc.. Started Sep 2014; status: completed.
02
Drugs
REP 2139-Mg
03
Conditions
hepatitis B (HBV)hepatitis D (HDV)
Beyond the preview
Go deeper on NCT02233075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02233075.